Dova Pharmaceuticals Inc (DOVA) Insider Sells $20,933.99 in Stock

Dova Pharmaceuticals Inc (NASDAQ:DOVA) insider Jason Hoitt sold 2,387 shares of Dova Pharmaceuticals stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $8.77, for a total value of $20,933.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of NASDAQ DOVA traded down $0.01 during midday trading on Wednesday, hitting $8.52. The stock had a trading volume of 198,489 shares, compared to its average volume of 176,513. The firm has a market capitalization of $240.78 million, a P/E ratio of -3.28 and a beta of 2.06. Dova Pharmaceuticals Inc has a 1-year low of $5.62 and a 1-year high of $35.33. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.73 and a quick ratio of 5.51.

Dova Pharmaceuticals (NASDAQ:DOVA) last released its quarterly earnings results on Tuesday, March 5th. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.08. The company had revenue of $2.84 million for the quarter, compared to analyst estimates of $3.48 million. On average, equities research analysts expect that Dova Pharmaceuticals Inc will post -2.31 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. raised its position in shares of Dova Pharmaceuticals by 14,705.9% in the 4th quarter. PNC Financial Services Group Inc. now owns 5,034 shares of the company’s stock valued at $38,000 after purchasing an additional 5,000 shares in the last quarter. Rhumbline Advisers raised its position in shares of Dova Pharmaceuticals by 46.1% in the 4th quarter. Rhumbline Advisers now owns 15,343 shares of the company’s stock valued at $116,000 after purchasing an additional 4,843 shares in the last quarter. Two Sigma Investments LP acquired a new position in shares of Dova Pharmaceuticals in the 4th quarter valued at approximately $136,000. Squarepoint Ops LLC acquired a new position in shares of Dova Pharmaceuticals in the 4th quarter valued at approximately $137,000. Finally, Stonepine Capital Management LLC acquired a new position in shares of Dova Pharmaceuticals in the 3rd quarter valued at approximately $145,000. 30.09% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have recently weighed in on DOVA. BidaskClub lowered Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday. HC Wainwright set a $18.00 price objective on Dova Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, March 5th. LADENBURG THALM/SH SH lifted their price objective on Dova Pharmaceuticals to $32.00 and gave the company a “buy” rating in a research note on Tuesday, December 18th. They noted that the move was a valuation call. Finally, JPMorgan Chase & Co. lowered Dova Pharmaceuticals from an “overweight” rating to an “underweight” rating and reduced their price objective for the company from $34.00 to $20.00 in a research note on Wednesday, January 23rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $29.57.

COPYRIGHT VIOLATION NOTICE: “Dova Pharmaceuticals Inc (DOVA) Insider Sells $20,933.99 in Stock” was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.com-unik.info/2019/04/10/dova-pharmaceuticals-inc-dova-insider-sells-20933-99-in-stock.html.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.

Further Reading: What is the Dow Jones Industrial Average (DJIA)?

Insider Buying and Selling by Quarter for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit